NAARDEN, THE NETHERLANDS / ACCESSWIRE / October 13, 2020 / NorthSea Therapeutics B.V., ('NST') a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, will present on October 15 at 11:20am EST, with one-on-one meetings to be held throughout the conference.
The presentation will be webcast live and available for replay: https://www.webcaster4.com/Webcast/Page/2408/37752
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email: firstname.lastname@example.org
About NorthSea Therapeutics
NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs') for the treatment of metabolic, inflammatory and fibrotic disorders. NST licensed the rights to its lead compound icosabutate and a library of discovery- and pre-clinical-stage SEFAs from Pronova BioPharma Norge AS, which developed Lovaza®, a blockbuster cardiovascular drug. Icosabutate has been found to be safe and effective in two prior Phase 2 clinical studies for the treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for non-alcoholic steatohepatitis (NASH). A Phase 2b study was initiated in the second half of 2019 (ICONA) to study the efficacy of icosabutate in NASH. The interim readout of the ICONA study will be available in Q1-2021. Two additional SEFA programs will go into the clinic; the SEFA-1024 phase 1 study will dose the first patient in Q4-2020 (dyslipidemia). For SEFA-6179 the start of the phase 1 study is scheduled for the first half of 2021 (PNALD, orphan indication). NST is based in the Netherlands and supported by a strong investors syndicate: Forbion (led the Series A round), Novo Seeds, BGV, NSV venBio Partners (led the Series B round) and Sofinnova Investments. Find out more about us online at www.northseatherapeutics.com.
SOURCE: NorthSea Therapeutics B.V.
View source version on accesswire.com: